Delving into the Latest Updates on Macera therapeutics with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

CAR-M

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

CAR-M	1

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	1

The goal of this exploratory clinical trial is to evaluate the safety and efficacy of human anti-human epidermal growth factor receptor 2(HER2) Chimeric antigen receptor macrophage cells (CAR-M) in advanced HER2+ gastric cancer. Participants will mobilize bone marrow stem cells and engineer autologous macrophages to express Chimeric antigen receptor (CAR), and CAR-M will be infused intraperitoneally back into the patient for systemic anti-tumor effects.

Start Date01 Mar 2024

Sponsor / Collaborator

The First People's Hospital of Hangzhou

[+1]

100 Clinical Results associated with Macera therapeutics

Login to view more data

0 Patents (Medical) associated with Macera therapeutics

Login to view more data

100 Deals associated with Macera therapeutics

Login to view more data

100 Translational Medicine associated with Macera therapeutics

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data